The Trump administration’s budget request for fiscal year 2020 (FY20) includes cuts that—if enacted—would hamstring the research and development (R&D) of new global health technologies. Since the release of the budget request in early March, however, lawmakers from both parties have expressed their commitment to shielding critical funding strings from the president’s scissors.
From the Breakthroughs Blog: PEPFAR
On February 15, President Trump signed into law a bipartisan spending bill—averting another partial government shutdown and ensuring full-year funding for the government for the remainder of fiscal year 2019. The months-long saga ended with some great news for global health and research and development.
On February 5, President Trump delivered his second State of the Union address. Among the long list of policy proposals and pledges in the speech was one of great interest to the global health research community—an announcement of a new whole-of-government plan to eliminate HIV transmission in the United States by 2030.
USAID’s latest report to Congress demonstrates how strategic R&D investments are driving positive global health outcomes and saving American taxpayers money
On Tuesday, the Trump Administration released its full fiscal year 2018 budget proposal. This budget proposes significant cuts to programs that support global health and medical research at the National Institutes of Health, Centers for Disease Control and Prevention, and the US Agency for International Development.
Trump budget proposes steep cuts to research and foreign assistance that will threaten global health research
What global health advocates need to know about the President's "skinny" budget.
As the DC summer kicks into full swing, Congress has had a busy month moving forward fiscal year (FY) 2015 funding legislation for a variety of government programs including global health research and development (R&D).
Yesterday, the White House released President Obama’s much-anticipated budget request for fiscal year (FY) 2015.
In this guest post, Jenny Howell—senior policy & advocacy associate at PATH working with the GHTC—writes about how the government shutdown and budget negotiations in Congress will impact global health research and development (R&D) programs across the federal government.
Investing in the future: GHTC congressional briefing highlights compelling benefits of global health research
“I’d be careful not to break something that would be hard to put back together,” Alan Magill—director of Malaria at the Bill and Melinda Gates Foundation—said this week at the GHTC’s annual congressional briefing.